Which of the following treatments would you recommend for this patient ?
**Question:** A 50-year-old female presents with type 2 diabetes mellitus poorly controlled despite multiple oral hypoglycemic agents. She is not a candidate for insulin therapy due to concerns about injection site reactions and fear of hypoglycemia. Which of the following treatments would you recommend for this patient?
A. Dapagliflozin
B. Empagliflozin
C. Sitagliptin
D. Pioglitazone
**Core Concept:** In patients with type 2 diabetes mellitus, SGLT2 inhibitors (e.g., dapagliflozin, empagliflozin) and SGLT1 inhibitors (e.g., sitagliptin) are effective adjunctive therapies for glycemic control, especially in patients who are not suitable for insulin therapy due to reasons like injection site reactions and fear of hypoglycemia.
**Why the Correct Answer is Right:** Dapagliflozin and empagliflozin are SGLT2 inhibitors, which decrease glucose reabsorption in the kidney, thereby increasing glucose excretion in the urine and leading to hypoglycemic effects. These drugs are beneficial in patients who cannot be started on insulin due to concerns regarding injection site reactions and hypoglycemia.
**Why Each Wrong Option is Incorrect:**
A. Sitagliptin (SGLT1 inhibitor) is incorrect because it is not suitable for patients who are not candidates for insulin therapy due to reasons like injection site reactions and fear of hypoglycemia.
B. Pioglitazone is incorrect as it is a PPAR-gamma agonist, primarily used for type 2 diabetes mellitus, but is not a suitable alternative to insulin therapy for the reasons mentioned (injection site reactions and fear of hypoglycemia).
**Why the Correct Answer is Right:**
**Clinical Pearl:** In patients with type 2 diabetes who cannot be started on insulin due to concerns regarding injection site reactions and hypoglycemia, SGLT2 inhibitors like dapagliflozin and empagliflozin are suitable options for glycemic control. These drugs provide additional benefits including weight loss and cardiovascular risk reduction.
**Why Each Wrong Option is Incorrect:**
A. Sitagliptin is not suitable for patients who cannot be started on insulin due to concerns regarding injection site reactions and fear of hypoglycemia.
B. Pioglitazone is not suitable for patients who cannot be started on insulin due to concerns regarding injection site reactions and fear of hypoglycemia, as it is a PPAR-gamma agonist primarily used for type 2 diabetes mellitus.